{{refimprove|date=August 2012}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458270691
| image =  
<!--Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = u
| target = [[CD30]]
<!--Clinical data -->
| tradename =  
| pregnancy_AU =  
| pregnancy_US =  
| pregnancy_category =  
| legal_AU =  
| legal_CA =  
| legal_UK =  
| legal_US =  
| legal_status =  
| routes_of_administration =  
<!--Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!--Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 640735-09-7
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04612
<!--Chemical data -->
| C=6358 | H=9830 | N=1682 | O=1992 | S=38
| molecular_weight = 170 kg/mol
}}

'''Iratumumab''' is a [[human]] [[monoclonal antibody]] used in the treatment of oncological diseases such as relapsed refractory [[CD30]]-positive lymphoma including [[Hodgkin's disease]].<ref>[http://www.ama-assn.org/ama1/pub/upload/mm/365/iratumumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council â€“ Iratumumab], ''American Medical Association''.</ref>

This drug was developed by [[Medarex]], which was later acquired by [[Bristol-Myers Squibb]].

The FDA granted [[orphan drug designation]] for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given.<ref name="Adis">{{cite web|title=Iratumumab|url=http://adisinsight.springer.com/drugs/800017758|website=AdisInsight|accessdate=30 January 2017}}</ref>

== References ==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Experimental cancer drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}